Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.

Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC.

Aliment Pharmacol Ther. 2015 Mar;41(6):544-63. doi: 10.1111/apt.13081. Epub 2015 Jan 26.

PMID:
25619871
2.

Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.

Stahmeyer JT, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen H, Hüppe D, Teuber G, Wiebner B, Wedemeyer H, Krauth C.

Eur J Gastroenterol Hepatol. 2014 Nov;26(11):1278-85. doi: 10.1097/MEG.0000000000000181.

PMID:
25144493
3.

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z.

Aliment Pharmacol Ther. 2014 Sep;40(6):657-75. doi: 10.1111/apt.12871. Epub 2014 Jul 28.

PMID:
25065960
4.

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.

Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, O'Brien J, Thalassinos E, Papastergiou V, Noel-Storr A, Davidson B, Burroughs AK.

Hepatology. 2014 Sep;60(3):832-43. doi: 10.1002/hep.27296. Epub 2014 Jul 29. Review.

5.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators.

N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.

6.

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

Hagan LM, Sulkowski MS, Schinazi RF.

Hepatology. 2014 Jul;60(1):37-45. doi: 10.1002/hep.27151. Epub 2014 May 14.

PMID:
24677184
7.

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).

Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y.

J Hepatol. 2014 Jul;61(1):7-14. doi: 10.1016/j.jhep.2014.03.011. Epub 2014 Mar 17.

PMID:
24650691
8.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
9.

Direct-acting antiviral agents in patients with hepatitis C cirrhosis.

Im GY, Dieterich DT.

Gastroenterol Hepatol (N Y). 2012 Nov;8(11):727-65.

10.

Hepatitis C virus infection and health-related quality of life.

Amodio P, Salari L, Montagnese S, Schiff S, Neri D, Bianco T, Minazzato L.

World J Gastroenterol. 2012 May 21;18(19):2295-9. doi: 10.3748/wjg.v18.i19.2295.

11.

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50. doi: 10.1097/MEG.0b013e3283513e69.

PMID:
22337287
12.

Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review.

Bota S, Sporea I, Popescu A, Sirli R, Neghina AM, Danila M, Strain M.

J Gastrointestin Liver Dis. 2011 Sep;20(3):293-8. Review.

13.

Chronic hepatitis C treatment in näive patients.

Daruich J.

Ann Hepatol. 2010;9 Suppl:65-71.

PMID:
20713999
14.

Quality of care in patients with chronic hepatitis C virus infection: a cohort study.

Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM.

Ann Intern Med. 2010 Aug 17;153(4):231-9. doi: 10.7326/0003-4819-153-4-201008170-00005.

PMID:
20713791
15.

The multidimensional burden of hepatitis C and its treatment: a case study.

Taylor-Young P, Hildebrandt E.

Gastroenterol Nurs. 2009 May-Jun;32(3):180-7. doi: 10.1097/SGA.0b013e3181a80655. Review.

PMID:
19506434
16.

Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition?

Perut V, Labalette C, Sogni P, Ferrand I, Salmon-Céron D, Vidal-Trecan G.

Drug Alcohol Depend. 2009 Sep 1;104(1-2):78-83. doi: 10.1016/j.drugalcdep.2009.04.002. Epub 2009 May 21.

PMID:
19464124
17.

Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.

Novick DM, Kreek MJ.

Addiction. 2008 Jun;103(6):905-18. doi: 10.1111/j.1360-0443.2008.02188.x. Epub 2008 Apr 16. Review.

19.

Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.

Department of Veterans Affairs Hepatitis C Resource Center, Yee HS, Currie SL, Darling JM, Wright TL.

Am J Gastroenterol. 2006 Oct;101(10):2360-78.

PMID:
17032203
20.

Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.

Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM.

Clin Gastroenterol Hepatol. 2005 Oct;3(10):1034-42.

PMID:
16234051
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk